171051-07-3

Upstream product

• 52605-49-9 sarcosine ethyl ester hydrochloride 
• 171050-45-6 3-[2-(2-Carboxymethyl-1-cyclohexenyl)-3-oxo-2,3-dihydropyridazin-6-yl]-2-phenylpyrazolo[1,5-a]-pyridine 
• 286-20-4 cyclohexane-1,2-epoxide 
• 822-87-7 2-Chlorocyclohexanone 
• 131185-06-3 3-(3-oxo-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo<1,5-a>pyridine 
• 171050-40-1 3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-(6H)-pyridazin-6-one-1-cyclohexan-2-one 
• 171051-34-6 tert-butyl 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-1-cyclohexenylacetate 

Relevant academic research and scientific papers

Pyrazolopyridine adenosine antagonists

The present invention relates to a novel pyrazolopyridine compound of the following formula: whereinR1 is aryl, andR2 is cyclo(lower)alkyl which may have one or more suitable substituent(s), etc;and a pharmaceutically acceptable salt thereof, which is useful as a medicament; the processes for the preparation of said pyrazolopyridine compound or a salt thereof; a pharmaceutical composition comprising said pyrazolopyridine compound or a pharmaceutically acceptable salt thereof; etc.

Novel adenosine A1 receptor antagonists. Synthesis and structure-activity relationships of a novel series of 3-(2-cyclohexenyl-3-oxo-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5 -a]pyridines.

A novel series of 3-(2-cyclohexenyl-3-oxo-2,3-dihydropyridazin-6-yl)-2-phenylpyrazol o[1,5-a]pyridines was synthesized and evaluated for in vitro adenosine A1 and A2A receptor binding activities. Most of the cyclohexenyl derivatives (7a-e, 8a-s) were found to be potent adenosine A1 receptor antagonists. In a series of analogues of FR166124 (3a), alcohol 7c, nitrile 7e and amide derivatives (7d, 8c, 8r) were found to be more potent A1 antagonists with higher A2A/A1 selectivity than FR166124. Amongst them, 8r showed considerable water solubility (33.3 mg/mL), but lower than that of the sodium salt of FR166124 (> 200 mg/mL). Additionally, FR166124 had strong diuretic activity by both p.o. and iv administration in rats (minimum effective dose=0.1 and 0.032 mg/kg, respectively).